Drug Trial Radar · NCT06469164
A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Jul 1, 2024
Primary completion
Jul 31, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).
Conditions
- Bacterial Vaginosis
Interventions
BNT331Drug
Vaginal insert
PlaceboOther
Vaginal insert
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 7 days post dose on Day 1
- Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 120 days after first dose on Day 1
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
UAB Sexual Health Research Clinic
Birmingham, Alabama
Praetorian Pharmaceutical Research, LLC
Marrero, Louisiana
Southern Clinical Research Associates - Metairie
Metairie, Louisiana
Women Under Study, LLC
New Orleans, Louisiana
Nucleus Network
Saint Paul, Minnesota
Chattanooga Medical Research, LLC
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.